TWI519323B - 含有聯苯乙酸之外用貼附劑 - Google Patents
含有聯苯乙酸之外用貼附劑 Download PDFInfo
- Publication number
- TWI519323B TWI519323B TW100139701A TW100139701A TWI519323B TW I519323 B TWI519323 B TW I519323B TW 100139701 A TW100139701 A TW 100139701A TW 100139701 A TW100139701 A TW 100139701A TW I519323 B TWI519323 B TW I519323B
- Authority
- TW
- Taiwan
- Prior art keywords
- weight
- acid
- biphenylacetic acid
- adhesive
- patch
- Prior art date
Links
- 229960000192 felbinac Drugs 0.000 title claims description 53
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 title description 50
- 239000000853 adhesive Substances 0.000 claims description 37
- 230000001070 adhesive effect Effects 0.000 claims description 36
- 238000002156 mixing Methods 0.000 claims description 25
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 16
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 claims description 15
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 14
- -1 diethyl diester Chemical class 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 239000013032 Hydrocarbon resin Substances 0.000 claims description 11
- 125000002723 alicyclic group Chemical group 0.000 claims description 11
- 229920006270 hydrocarbon resin Polymers 0.000 claims description 11
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 11
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 claims description 3
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 claims description 3
- YWPABLWXCWUIIT-UHFFFAOYSA-N 2-(2-phenylphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1C1=CC=CC=C1 YWPABLWXCWUIIT-UHFFFAOYSA-N 0.000 claims 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 239000003822 epoxy resin Substances 0.000 claims 1
- 229920000647 polyepoxide Polymers 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 35
- 239000003814 drug Substances 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 206010040880 Skin irritation Diseases 0.000 description 12
- 230000036556 skin irritation Effects 0.000 description 12
- 231100000475 skin irritation Toxicity 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000012790 adhesive layer Substances 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 229920001083 polybutene Polymers 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 239000002759 woven fabric Substances 0.000 description 3
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 201000011275 Epicondylitis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010034464 Periarthritis Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- 208000002240 Tennis Elbow Diseases 0.000 description 2
- 208000004760 Tenosynovitis Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 2
- 229960001395 fenbufen Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 229920003049 isoprene rubber Polymers 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本發明係有關一種經皮吸收性外用消炎鎮痛製劑，詳言之，係有關一種顯示良好的藥物釋放性、皮膚刺激性低且具有高藥物穩定性之含有聯苯乙酸之消炎鎮痛外用貼附劑。
聯苯乙酸(Felbinac：4-聯苯乙酸)係非類固醇系消炎鎮痛藥芬布芬(fenbufen，聯苯丁酮酸)的活性代謝物，是一種顯示強力消炎鎮痛作用的藥物。若經口投予聯苯乙酸，則會對消化系統產生副作用而有發生胃腸損傷的問題，由此便對經皮吸收型製劑進行探討，迄今市售有凝膠劑、液劑等外用製劑。
然而，如凝膠劑、液劑之劑形存有難以進行定量投予、生物學上之利用率低，及製劑沾附於衣服上等問題。
為改善此種凝膠劑、液劑之問題，以聯苯乙酸為首，既已開發有含各種消炎鎮痛藥的水性貼附劑(泥罨劑(cataplasm))、油性貼附劑(硬膏劑(plaster))。特別是油性貼附劑(硬膏劑)因未有貼附時的冰冷感等原因，業已成為非類固醇系消炎鎮痛貼附劑的主流，而具組合有橡膠系基劑與增黏樹脂之配方者亦經廣泛使用。
在非類固醇系消炎鎮痛貼附劑中，一般為了提高藥物的經皮吸收性而摻混有各種添加劑。特別是L-薄荷醇係有用於作為聯苯乙酸的溶解劑，是一種與多數市售含有聯苯乙酸之貼附劑摻混的添加劑。惟，另一方面已知聯苯乙酸與L-薄荷醇反應會生成作為分解生成物的L-薄荷醇酯體，摻混L-薄荷醇茲認為係貼附劑中聯苯乙酸的穩定性惡化的原因之一。
此外，多數人亦對伴隨L-薄荷醇的昇華而生之刺激性臭味感到不適，且市場上對未摻混有L-薄荷醇、或可抑制L-薄荷醇臭味之貼附製劑的需求高漲同為實情。
其他，為提高聯苯乙酸的經皮吸收性，自昔至今已對摻混克羅他命酮、脂肪酸、脂肪酸酯、單萜烯類、多元醇類、吡咯啶酮類等經皮吸收促進劑進行探討。
舉例而言，專利文獻1中提出有一種具備黏著劑層的含有聯苯乙酸之貼附劑，該黏著劑層含有對聯苯乙酸的溶解能力優良的克羅他命酮為主要成分。然而，克羅他命酮有容易由黏著劑層表面滲出而使黏著力歷時性下降的問題。
又，專利文獻2中揭示有一種以苯乙烯-異戊二烯-苯乙烯嵌段共聚物為黏著劑，且組合摻混有L-薄荷醇與各種吸收促進劑之聯苯乙酸摻混消炎鎮痛貼布。然而，與該貼布摻混之L-薄荷醇係如前述，可能與聯苯乙酸反應而生成分解生成物，更有組合摻混L-薄荷醇與吸收促進劑時引起基劑物性的惡化及皮膚刺激性之虞。
同樣專利文獻3中揭示有一種摻混有萜烯、癸二酸酯、烷基甘油醚的含有聯苯乙酸之貼附劑，其與專利文獻2相同的是，對於藥物穩定性、基劑物性及皮膚刺激性仍有改善的空間。
其他，既已探討組合摻混有N-甲基-2-吡咯啶酮與聚乙二醇的聯苯乙酸貼附劑(專利文獻4)、摻混硬化油者(專利文獻5)等摻混有各種經皮吸收促進劑的貼附劑，但仍未發現兼備高藥物經皮吸收性與安全性、及優良之藥物穩定性的經皮吸收製劑。
另一方面，亦已嚐試利用摻混經皮吸收促進劑之方法以外的手段來提高藥物之經皮吸收性。
例如，專利文獻6揭示一種在以苯乙烯-異戊二烯-苯乙烯嵌段共聚物為基材之黏著劑基劑中摻混羊毛脂，並使羊毛脂保持水分的含水型硬膏劑。
此為擬透過製劑中所含之水分來提高聯苯乙酸之溶解性，由此提升經皮吸收性之試行，然，使水分含於油性貼附劑中會使製造步驟複雜化，且無法完全排除保存中之製劑的物性降低的可能性。
再者，其有相較於使用經皮吸收促進劑之硬膏劑，經皮吸收性方面略差的問題。
專利文獻7中提出一種貼附劑，其未使用克羅他命酮，而是以苯乙烯-異戊二烯-苯乙烯嵌段共聚物為主基劑，並使聯苯乙酸均勻分散於摻混有松香系樹脂等的黏著基劑中。
然而，與該貼附劑摻混之松香系樹脂已知其作用為皮膚過敏(cutaneous sensitization)成分，予以摻混時較不理想。所謂「皮膚過敏」係指延遲性過敏反應的一種，乃由化學物質引起過剩的免疫反應而使皮膚發生腫癢等的現象。
[專利文獻1]日本特開平4-321624號公報
[專利文獻2]日本特開平10-218793號公報
[專利文獻3]日本特開2008-13494號公報
[專利文獻4]日本特開2001-342130號公報
[專利文獻5]日本特開2007-8927號公報
[專利文獻6]日本特開2001-97857號公報
[專利文獻7]國際公開WO98/24423號
本發明係用於解決上述問題，課題在於提供一種即便未摻混作為聯苯乙酸之優良溶解劑的L-薄荷醇亦顯示高藥物釋放性，且皮膚刺激性低、可發揮高藥物穩定性之含有聯苯乙酸之外用貼附劑。
本發明者為解決前述課題而戮力進行多次研究的結果發現，在含有苯乙烯-異戊二烯-苯乙烯嵌段共聚物、脂環族飽和烴樹脂、軟化劑及癸二酸二乙酯而未含有L-薄荷醇之黏著劑基劑中分散摻混平均粒徑為5μm以上且小於100μm的聯苯乙酸，便可製成皮膚刺激性低、兼備聯苯乙酸的優良藥物釋放性與藥物穩定性的外用貼附劑，本發明即臻完成。
因此本發明之基本形態為一種以在不含有L-薄荷醇，而包含苯乙烯-異戊二烯-苯乙烯嵌段共聚物、脂環族飽和烴樹脂、軟化劑及癸二酸二乙酯之黏著基劑中分散摻混有平均粒徑為5μm以上且小於100μm的聯苯乙酸為特徵之含有聯苯乙酸之外用貼附劑。
更具體之本發明為一種以在不含有L-薄荷醇，而包含苯乙烯-異戊二烯-苯乙烯嵌段共聚物10~30重量%、脂環族飽和烴樹脂10~50重量%、軟化劑10~75重量%、癸二酸二乙酯0.1~10重量%之黏著劑基劑中分散摻混有平均粒徑為5μm以上且小於100μm的聯苯乙酸0.1~10重量%為特徵之含有聯苯乙酸之外用貼附劑。
根據本發明，可提供一種在含有聯苯乙酸之經皮吸收製劑中顯示優良的藥物釋放性、皮膚刺激性低並顯示高藥物穩定性之含有聯苯乙酸之外用貼附劑。
本發明所提供之含有聯苯乙酸之外用貼附劑可因聯苯乙酸的優良消炎鎮痛效果，如有用於預防、治療退化性關節炎、慢性類風濕性關節炎、腰痛、肩關節周圍炎、腱鞘炎、腱周圍炎、肱骨外上髁炎(網球肘等)、肌肉痛、外傷後的腫脹、疼痛等。
本發明係如上述，其基本形態為一種以在不含有L-薄荷醇，而包含苯乙烯-異戊二烯-苯乙烯嵌段共聚物、脂環族飽和烴樹脂、軟化劑及癸二酸二乙酯之黏著基劑中分散摻混有平均粒徑為5μm以上且小於100μm的聯苯乙酸為特徵之含有聯苯乙酸之外用貼附劑。
即，本發明之特徵為，作為有效成分之聯苯乙酸特別係使用平均粒徑為5μm以上且小於100μm的聯苯乙酸，並使之分散於黏著基劑層中。
本發明中，只要可製劑化，作為有效成分之聯苯乙酸於製劑中的摻混量則未特別限定，較佳為相對黏著劑重量，宜於0.1~10重量%，更佳為0.5~6重量%之範圍內摻混。
若黏著劑中的聯苯乙酸摻混量小於0.1重量%時，經皮吸收性便不充分而無法確認出效果，又即使摻混超過10重量%，亦無法確認出進一步之效果，經濟上較不利而不佳。
又，就本製劑中所摻混之聯苯乙酸而言，若考量在黏著劑中之分散性、或製造步驟之作業性，則以使用其平均粒徑為5μm以上且小於100μm，較佳為10μm以上且小於70μm，特佳為15μm以上且小於40μm之範圍者為佳。
其平均粒徑若小於5μm，則於製造步驟中聯苯乙酸原藥會發生二次凝聚而有分散不均勻之虞，導致藥物之經皮吸收性降低。反之平均粒徑若為100μm以上，藥物在黏著劑中可能分散不均勻。特別是當粒徑較大時，遑論藥物之經皮吸收性降低，在製造步驟，特別是塗布黏著劑成剝離膜之步驟中亦發現不良影響。即，有時聯苯乙酸原藥在製造時發生凝聚，而可見由此所生之黏著劑表面的凹凸。
本發明所摻混之苯乙烯-異戊二烯-苯乙烯嵌段共聚物(以下有簡記為SIS)係作為黏著劑之基本骨架的合成橡膠，其摻混量係於10~30重量%，較佳為10~20重量%之範圍內摻混。若SIS之摻混量低於10重量%時，黏著劑之凝聚力會降低，另一方面若上述摻混量摻混超過30重量%時則導致黏著力下降及製造時的作業性降低。
本發明中，若考量增黏樹脂對皮膚的安全性，可較佳使用脂環族飽和烴樹脂。作為此種脂環族飽和烴樹脂可例舉如ARKON P90、P100、P115(荒川化學工業公司製)等。
只要可製劑化，其摻混量則未特別限定，較佳為相對黏著劑重量，宜於10~50重量%之範圍內摻混。
黏著劑中的脂環族飽和烴樹脂含量若低於10重量%時黏著力弱，而摻混超過50重量%時則製劑之黏著力增強，存在剝離時伴有痛感的問題。
本發明中所使用之癸二酸二乙酯係發揮作為聯苯乙酸之皮膚吸收促進劑的功能。只要可製劑化，該癸二酸二乙酯之摻混量則未特別限定，較佳為相對黏著劑重量，宜於0.1~10重量%，較佳為1~7重量%之範圍內摻混。
黏著劑中的癸二酸二乙酯摻混量若低於0.1重量%時，聯苯乙酸之皮膚穿透性會不充分，摻混超過10重量%時則發生皮膚刺激等問題而不佳。
本發明中，顯然聯苯乙酸與癸二酸二乙酯之摻混比對於經皮吸收性亦為重要之因素。即，可知以重量%言，宜於聯苯乙酸：癸二酸二乙酯=1：0.1~1：15之範圍，較佳為聯苯乙酸：癸二酸二乙酯1：0.5~1：10之範圍。
摻混比例若小於1：0.1時便無法獲得癸二酸二乙酯所產生的吸收促進效果，未得充分的藥物吸收性。又摻混比例超過1：15時，則聯苯乙酸會溶於過量的癸二酸二乙酯中而形成藥物穩定性低之製劑。
本發明所摻混之軟化劑可賦予黏著劑柔軟性，可例舉液態聚丁烯、液態聚異戊二烯、液態聚異丁烯等液態橡膠；流動石蠟等石蠟油；肉豆蔻酸異丙酯、己二酸二異丙酯等脂肪酸酯類；辛基十二醇等高級醇；矽油；羊毛脂；鯊烷；鯊烯；蓖麻油等，而較佳為液態聚丁烯及流動石蠟。
相對黏著劑重量，軟化劑之摻混量宜於10~75重量%，較佳為15~60重量%，更佳為20~50重量%之範圍內摻混。
其他，就本發明外用貼附劑而言，只要未造成其他影響，則可使用一般外用製劑所使用的各種基劑成分。作為所述基劑成分並未特別限定，可例舉如苯乙烯-丁二烯-苯乙烯嵌段共聚物、苯乙烯‧丁二烯橡膠、天然橡膠、異戊二烯橡膠等橡膠系彈性體；聚丙烯酸系聚合物、矽氧橡膠等疏水性高分子；二丁基羥基甲苯、新戊四醇-四-[3-(3,5-二-三級丁基-4-羥苯基)丙酸酯]、生育酚(維生素E)乙酸酯等抗氧化劑；氫氧化鋁、含水矽酸鋁、氧化鈦、氧化鋅、矽酸酐、矽酸鎂等無機填充劑等。可進一步視需求添加吸收促進劑、防腐劑、清涼劑、殺菌劑、芳香劑、著色劑等。
就本發明貼附劑之支持物(support)而言，只要未造成其他影響，則可使用一般外用製劑所使用的各種支持物。作為所述支持物並未特別限定，可使用與例如聚乙烯、聚丙烯、聚氯乙烯、聚酯、尼龍、聚胺基甲酸酯、嫘縈(rayon)等多孔體、發泡體(foam body)、織布、不織布之積層品等。
就本發明貼附劑所使用之釋離襯墊(release liner)而言，只要未造成其他影響，則可使用一般外用製劑所使用的各種襯墊。作為所述釋離襯墊並未特別限定，可採用例如聚對苯二甲酸乙二酯薄膜、聚丙烯薄膜、紙等，特佳為聚對苯二甲酸乙二酯薄膜。為使來自黏著劑層的剝離力最佳化，釋離襯墊可視需求而實施有矽氧處理。
本發明所提供之外用貼附劑例如可由以下方式來製造。
亦即，加熱使構成黏著劑層的SIS、軟化劑、及脂環族飽和烴樹脂、抗氧化劑溶解。次之，將有效成分聯苯乙酸、與癸二酸二乙酯添加至前述黏著基劑混合物中並攪拌、混合，來調製貼附劑中的黏著劑。
其次，將調製之黏著劑(膏狀物)塗布於經矽氧處理的聚對苯二甲酸乙二酯薄膜上，形成厚50~300μm的黏著劑層。於所得之黏著劑層上積層支持物聚酯製織布或不織布後，裁切成適當的大小暨形狀，即可製得本發明外用貼附劑。
以下舉出具體實施例來更具體地說明本發明，惟本發明並未受限於以下實施例。
此外，實施例及比較例之各表中的摻混成分的摻混量只要未予特別事先說明，則以「重量%」表示之。
在170℃加熱條件下揉合(knead)SIS、聚丁烯、流動石蠟、二丁基羥基甲苯使其溶融後，進一步添加脂環族飽和烴樹脂，並在130℃加熱條件下予以揉合、混合來製作黏著基劑。
另外，一面攪拌平均粒徑為5μm以上且小於100μm的聯苯乙酸，一面使其均勻分散於混有癸二酸二乙酯與適量流動石蠟的液體中，來調製聯苯乙酸分散液。將該聯苯乙酸分散液添加至上述黏著基劑中，揉合至均勻分散為止來調製黏著劑。將黏著劑塗布於經矽氧處理的聚對苯二甲酸乙二酯薄膜上成100μm厚之後，與聚酯織布積層即得試驗製劑。
以與實施例1相同的步驟，根據表1~表3所示的成分組成來製作目標本發明貼附劑。
除改為下述表4所示的成分組成以外，係以與實施例1相同的步驟來製作各比較例的外用貼附劑。
此外，比較例7之製劑在製造時(調製黏著劑時)因聯苯乙酸原藥發生凝聚，製劑表面可見凹凸，無法進行以下的製劑評定試驗。
將實施例1~2與比較例1~2之製劑各衝切成φ25mm，並貼附於15名健全男子的上臂內側24小時，判定剝離後1小時及24小時的皮膚刺激性。
其結果係示於下述表5。
由表5所示之結果可知，相較於比較例1~2，本發明外用貼附劑之實施例1~2之製劑其皮膚刺激性較低。
將實施例1與比較例3~4之製劑各衝切成5cm×7cm，並貼附於6名健全男子的背部12小時，萃取回收之製劑中所殘留的藥物並以HPLC測定藥物量。
由貼附0小時之藥物量減去殘留藥物量來計算藥物消失量。其結果係示於下述表6。
由表6所示之結果可知，相較於比較例3~4，本發明貼附劑之實施例1之製劑係藥物消失量高、經皮吸收性高的製劑。
以40℃保存實施例1、比較例2及比較例5之樣本(7cm×10cm)3個月後，萃取試驗製劑中的藥物並測定聯苯乙酸含量。
對比試驗前之各樣本的聯苯乙酸含量(初始值)，以相對初始值(%)算出。其結果係示於表7。
由表7所示之結果可知，相較於比較例2或比較例5，本發明外用貼附劑之實施例1其藥物穩定性優良。
將實施例1、實施例16及比較例6之各製劑各衝切成φ20mm，在容量100mL的燒杯內側側面，使用雙面膠以黏著劑面面向燒杯內側的方式貼附之。
製劑的貼附位置係調整成製劑最下端的部分為燒杯底部算起約30mm的位置。其後，對燒杯內側注入100mL的釋放溶液(PBS緩衝溶液)，並以磁性定子(magnetic stator)攪拌釋放溶液。爾後以高效液相層析法測定試驗開始90分鐘後之釋放溶液中的聯苯乙酸含量，並算出主藥之釋放率。其結果係示於表8。
由表8所示之結果可知，相較於比較例6之製劑，本發明外用貼附劑之實施例1及實施例16其主藥之釋放性格外優異。
根據本發明，可提供一種顯示良好的藥物釋放性、皮膚刺激性低並具有高藥物穩定性之含有聯苯乙酸之消炎鎮痛外用貼附劑。
本發明之外用貼附劑係有用於預防、治療如退化性關節炎、慢性類風濕性關節炎、腰痛、肩關節周圍炎、腱鞘炎、腱周圍炎、肱骨外上髁炎(網球肘等)、肌肉痛、外傷後的腫脹、疼痛等，其利用性極廣。
Claims (2)
- 一種含有聯苯乙酸之外用貼附劑，其特徵為在不含有L-薄荷醇，而包含苯乙烯-異戊二烯-苯乙烯嵌段共聚物、脂環族飽和烴樹脂、軟化劑及癸二酸二乙酯之黏著基劑中分散摻混有平均粒徑為5μm以上且小於100μm的聯苯乙酸，且進一步使聯苯乙酸與癸二酸二乙酯之摻混比例為1：0.1~1：15之範圍內。
- 一種含有聯苯乙酸之外用貼附劑，其特徵為在不含有L-薄荷醇，而包含苯乙烯-異戊二烯-苯乙烯嵌段共聚物10~30重量%、脂環族飽和烴樹脂10~50重量%、軟化劑10~75重量%、癸二酸二乙酯0.1~10重量%之黏著基劑中分散摻混有平均粒徑為5μm以上且小於100μm的聯苯乙酸0.1~10重量%，且進一步使聯苯乙酸與癸二酸二乙酯之摻混比例為1：0.1~1：15之範圍內。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010246666 | 2010-11-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201304824A TW201304824A (zh) | 2013-02-01 |
| TWI519323B true TWI519323B (zh) | 2016-02-01 |
Family
ID=46024490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW100139701A TWI519323B (zh) | 2010-11-02 | 2011-11-01 | 含有聯苯乙酸之外用貼附劑 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9833417B2 (zh) |
| EP (1) | EP2636405B1 (zh) |
| JP (1) | JP5856975B2 (zh) |
| KR (1) | KR101900519B1 (zh) |
| CN (1) | CN103269696B (zh) |
| AU (1) | AU2011324394B2 (zh) |
| CA (1) | CA2815792C (zh) |
| ES (1) | ES2669306T3 (zh) |
| TW (1) | TWI519323B (zh) |
| WO (1) | WO2012060376A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7374045B2 (ja) | 2020-06-02 | 2023-11-06 | 三菱電機株式会社 | 負担調整回路 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3541849B2 (ja) * | 1991-04-19 | 2004-07-14 | 久光製薬株式会社 | 消炎鎮痛貼付剤 |
| JPH07233050A (ja) * | 1994-02-23 | 1995-09-05 | Sekisui Chem Co Ltd | 外用貼付剤 |
| PT782855E (pt) * | 1994-10-05 | 2001-12-28 | Helsinn Healthcare Sa | Agente anti-inflamatorio para uso externo |
| JP3782834B2 (ja) * | 1994-10-26 | 2006-06-07 | 株式会社トクホン | 鎮痛抗炎症貼付剤 |
| JP3495733B2 (ja) * | 1996-12-06 | 2004-02-09 | 久光製薬株式会社 | フェルビナク含有貼付剤 |
| CA2274120A1 (en) * | 1996-12-06 | 1998-06-11 | Hisamitsu Pharmaceuticals Co., Inc. | Plaster containing felbinac |
| US6620430B2 (en) * | 1996-12-06 | 2003-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Plaster containing felbinac |
| JPH10218793A (ja) | 1997-02-03 | 1998-08-18 | Nichiban Co Ltd | 経皮吸収型消炎鎮痛用テープ剤及びその製造方法 |
| JP4676042B2 (ja) | 1999-10-01 | 2011-04-27 | 帝國製薬株式会社 | フェルビナク含有鎮痛・消炎外用貼付剤 |
| WO2001078690A1 (fr) * | 2000-04-18 | 2001-10-25 | Hisamitsu Pharmaceutical Co., Inc. | Piece contenant un agent anti-inflammatoire |
| JP4648518B2 (ja) | 2000-06-01 | 2011-03-09 | 帝國製薬株式会社 | ４−ビフェニル酢酸含有貼付剤 |
| ATE553756T1 (de) * | 2000-11-29 | 2012-05-15 | Teikoku Seiyaku Kk | Adhäsive zubereitung zur externen anwendung |
| JP4627985B2 (ja) * | 2001-05-31 | 2011-02-09 | 久光製薬株式会社 | 経皮吸収型貼付剤 |
| TWI341736B (en) * | 2003-12-26 | 2011-05-11 | Hisamitsu Pharmaceutical Co | Anti-infammatory adhesive preparations |
| TWI414320B (zh) | 2004-05-13 | 2013-11-11 | Hisamitsu Pharmaceutical Co | 含有非類固醇系消炎鎮痛劑之外用經皮製劑 |
| CN101080219B (zh) * | 2004-12-15 | 2010-11-17 | 帝国制药株式会社 | 含依托芬那酯的外用贴剂 |
| JPWO2006118173A1 (ja) * | 2005-04-28 | 2008-12-18 | 小野薬品工業株式会社 | 経皮吸収製剤 |
| JP4939113B2 (ja) | 2005-06-01 | 2012-05-23 | ニプロパッチ株式会社 | 貼付剤 |
| JP4920206B2 (ja) | 2005-06-30 | 2012-04-18 | ライオン株式会社 | 外用剤組成物及び貼付剤、並びに薬物の経皮吸収組成物 |
| JP5185509B2 (ja) * | 2006-04-28 | 2013-04-17 | ライオン株式会社 | 貼付剤 |
| JP5085062B2 (ja) * | 2006-07-06 | 2012-11-28 | リンテック株式会社 | 経皮吸収貼付剤 |
| JP5078303B2 (ja) * | 2006-09-15 | 2012-11-21 | 東光薬品工業株式会社 | 消炎鎮痛クリーム製剤及びその製造方法 |
| JP4590418B2 (ja) * | 2007-01-25 | 2010-12-01 | ニチバン株式会社 | 消炎鎮痛貼付剤 |
| PT2345426E (pt) * | 2008-09-19 | 2014-06-09 | Activus Pharma Co Ltd | Composto orgânico compósito em pó para utilização médica, método de produção do mesmo e suspensão do mesmo |
-
2011
- 2011-11-01 CA CA2815792A patent/CA2815792C/en active Active
- 2011-11-01 CN CN201180063899.6A patent/CN103269696B/zh active Active
- 2011-11-01 ES ES11838026.0T patent/ES2669306T3/es active Active
- 2011-11-01 KR KR1020137013618A patent/KR101900519B1/ko active IP Right Grant
- 2011-11-01 AU AU2011324394A patent/AU2011324394B2/en active Active
- 2011-11-01 US US13/882,747 patent/US9833417B2/en active Active
- 2011-11-01 EP EP11838026.0A patent/EP2636405B1/en active Active
- 2011-11-01 JP JP2012541875A patent/JP5856975B2/ja active Active
- 2011-11-01 TW TW100139701A patent/TWI519323B/zh active
- 2011-11-01 WO PCT/JP2011/075182 patent/WO2012060376A1/ja active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011324394A1 (en) | 2013-05-23 |
| TW201304824A (zh) | 2013-02-01 |
| WO2012060376A1 (ja) | 2012-05-10 |
| US9833417B2 (en) | 2017-12-05 |
| KR20140005887A (ko) | 2014-01-15 |
| AU2011324394B2 (en) | 2016-02-25 |
| KR101900519B1 (ko) | 2018-09-19 |
| EP2636405A1 (en) | 2013-09-11 |
| CA2815792C (en) | 2019-01-08 |
| CA2815792A1 (en) | 2012-05-10 |
| CN103269696A (zh) | 2013-08-28 |
| ES2669306T3 (es) | 2018-05-24 |
| JP5856975B2 (ja) | 2016-02-10 |
| EP2636405B1 (en) | 2018-03-14 |
| US20130236516A1 (en) | 2013-09-12 |
| EP2636405A4 (en) | 2014-04-23 |
| CN103269696B (zh) | 2015-04-01 |
| JPWO2012060376A1 (ja) | 2014-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4865958B2 (ja) | 鎮痛抗炎症局所作用型の貼付剤 | |
| JP5581080B2 (ja) | 外用貼付剤 | |
| JP6021269B2 (ja) | 非水性貼付剤 | |
| JPH1135458A (ja) | ジクロフェナクナトリウム含有油性外用貼付製剤 | |
| JP5858960B2 (ja) | 経皮吸収型鎮痛消炎貼付剤 | |
| WO2003070228A1 (fr) | Platre de type a absorption percutanee | |
| WO2004100959A1 (ja) | エストロゲン及び／又はプロゲストゲン含有外用貼付剤 | |
| JPWO2012153396A1 (ja) | 非水性貼付剤 | |
| WO2006092829A1 (ja) | フルルビプロフェン含有外用貼付剤 | |
| JP5285279B2 (ja) | 経皮吸収型製剤 | |
| JP2010280634A (ja) | 消炎鎮痛貼付剤 | |
| WO2006048939A1 (ja) | 非ステロイド消炎鎮痛薬を含有する非水系経皮吸収製剤 | |
| JP5684441B2 (ja) | インドメタシン含有貼付剤 | |
| JP2008179564A (ja) | 消炎鎮痛貼付剤 | |
| WO2005102306A1 (ja) | 消炎鎮痛貼付剤 | |
| TWI526227B (zh) | 含有洛索普洛芬鈉之外用貼附劑 | |
| TWI519323B (zh) | 含有聯苯乙酸之外用貼附劑 | |
| JP2016094446A (ja) | 非水性貼付剤 | |
| WO2022186351A1 (ja) | ロキソプロフェン含有貼付剤およびその製造方法 |